Code | CSB-RA929304A0HU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
WB | 1:500-1:5000 |
The process of producing a DRD3 recombinant antibody involves four key steps. Firstly, the DRD3 monoclonal antibody gene is sequenced. Secondly, the gene is cloned into a plasmid vector. Thirdly, the recombinant vector is introduced into a host cell line. Fourthly, the DRD3 recombinant monoclonal antibody is purified from the cell culture supernatant using affinity chromatography. The DRD3 monoclonal antibody is derived from the DRD3 antibody-producing hybridomas. During its production, a synthesized peptide that is derived from human DRD3 is used as the immunogen. The resulting DRD3 recombinant monoclonal antibody is recommended for use in ELISA and WB applications to detect human and mouse DRD3 proteins.
The DRD3 protein is a member of the G protein-coupled receptor family that is activated by the neurotransmitter dopamine. When dopamine binds to DRD3, it causes a conformational change in the receptor that activates downstream signaling pathways, including the cAMP/PKA and PI3K/Akt pathways. DRD3 is primarily expressed in the brain, particularly in areas involved in reward, cognition, and movement control, and is thought to play a role in regulating these processes. Abnormalities in DRD3 signaling have been implicated in a number of psychiatric and neurological disorders, including schizophrenia, addiction, and Parkinson's disease.
There are currently no reviews for this product.